We use cookies for a better user experience. Read our Privacy Policy
I Agree
Hepatitis Therapeutics Market Forecast Report, 2018-2026
Hepatitis is defined as the inflammation of liver. The most common forms of hepatitis are hepatitis A, B, and C. According to the statistics by the World Health Organization (WHO), nearly 325 million people are living with hepatitis infections across the globe. These statistics highlight the growing prevalence of hepatitis around the world. The need for reducing the burden on healthcare sectors due to hepatitis is pushing the demand for hepatitis therapeutics extensively, which in turn, is estimated to work as growth accelerators for the hepatitis therapeutics market.
The growing alcohol and drugs consumption coupled with sizeable population groups living in unhygienic conditions are resulting into increased cases of hepatitis infection. Therefore, the hepatitis therapeutics market is estimated to observe exponential growth on the basis of these factors. The growing awareness about the importance of hepatitis eradication among various countries and global organizations will serve as a key factor for the growth of the hepatitis therapeutics market. For instance, the WHO, in 2016 provided a guideline for viral hepatitis elimination by 2030. Furthermore, different initiatives such as the World Hepatitis Day are helping government bodies to spread awareness about hepatitis. Such initiatives serve as growth accelerators for the hepatitis therapeutics market.
Companies are investing in R&D projects in order to develop novel technologies. This factor is prognosticated to contribute to the growth of the hepatitis therapeutics market. Moreover, players are involving in mergers, acquisitions, joint ventures, and partnerships for expansion initiatives. All these aspects eventually help in increasing the growth rate of the hepatitis therapeutics market. Many countries are focusing on improving their healthcare policies to provide quality treatment to its citizens. Favorable reimbursement policies by government bodies of numerous countries are projected to serve as growth propellers for the hepatitis therapeutics market.
Hepatitis is the inflammation of the liver caused due to a viral infection. Hepatitis is one of the leading causes for health care burden in developed as well as developing countries. As per the WHO, around 1.75 million new HCV infections occur each year, and approximately 399,400 deaths were caused due to HCV in 2015. Increase in the usage of unsterilized equipment and infected syringes, medication errors, and transfusion of infectious blood are leading to an increase in the incidence of viral diseases such as Hepatitis C. This, in turn, is likely to fuel demand for hepatitis therapeutics across the globe. The global hepatitis therapeutics market was valued at US$ 22,049.2 Mn in 2017. It is projected to expand at a CAGR of 2.3% from 2018 to 2026.
The global hepatitis therapeutics market has been segmented based on disease type, drug class, distribution channel, and region. In terms of disease type, the global market has been categorized into hepatitis A, hepatitis B, hepatitis C, and others. The hepatitis C segment is anticipated to account for a major share of the market over the forecast period, owing to a high incidence rate of hepatitis C across the globe. Based on drug class, the global hepatitis therapeutics market has been classified into NS5A inhibitors, nucleotide analog reverse transcriptase inhibitors, nucleotide analog NS5B polymerase inhibitors, multi-class combination, interferon & ribavirin, and others. In terms of distribution channel, the global market has been divided into hospital pharmacies, retail pharmacies, and others.
In terms of region, the global hepatitis therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a major share of the global market in 2017. Rise in the incidence of and mortality caused due to hepatitis and increased spending on drugs for the treatment of hepatitis in the U.S. are likely to boost the hepatitis therapeutics market in the region. Europe is anticipated to account for a significant share of the global market between 2018 and 2026. The presence of well-established infrastructure, rise in demand for hepatitis drugs for the early treatment of the disease, and high viraemic prevalence in Eastern Europe are expected to fuel the growth of the market in the region during the forecast period. The market in Asia Pacific is likely to expand at a significant CAGR during the forecast period. Increasing prevalence of chronic hepatitis C in developing countries such as China and India and favorable government initiatives for creating awareness about hepatitis are projected to propel the market in the region in the next few years.
Key players operating in the global hepatitis therapeutics market include Gilead Sciences, Inc., Bristol Myers Squibb, F. Hoffmann-La Roche, Ltd., Merck & Co., Inc., LAURUS Labs, Zydus Cadila, AbbVie Inc., Cipla, Inc., Hetero Healthcare Limited, and NATCO Pharma Limited. These companies focus on developing novel drugs for the effective treatment of chronic hepatitis to enhance market foothold.
Novel Drug Formulations and Heightening Cases of Hepatitis to Accelerate the Growth Opportunities across the Hepatitis Therapeutics Market
The hepatitis therapeutics market is anticipated to observe considerable growth across the assessment period of 2018-2026. The growing number of hepatitis infected patients and the extensive consumption of alcohol and drugs in increasing the growth opportunities during the forecast period.
Hepatitis is a condition that causes inflammation of the liver. It mainly occurs due to high consumption of alcohol or drugs. In most cases, it is generally caused due to a virus known as viral hepatitis. The therapeutics related to hepatitis are known as hepatitis therapeutics. Novel formulations and an increase in the demand for drugs treating hepatitis will bring tremendous growth opportunities for the hepatitis therapeutics market.
Research and development activities play a major role in the growth of the hepatitis therapeutics market. The players invest heavily in these activities for developing novel formulations that assist in treating hepatitis at a faster rate. These factors help in increasing the revenues of the players in the hepatitis therapeutics market.
Strategic collaborations also play a crucial role in the growth of the hepatitis therapeutics market. The players indulge in activities such as mergers, acquisitions, joint ventures, and partnerships for increasing their foothold across the hepatitis therapeutics market, eventually boosting the growth rate.
Favorable reimbursement policies in various regions and an increase in the spending of the government bodies of numerous countries on healthcare infrastructure will prove to be a vital growth generator for the hepatitis therapeutics market.
The COVID-19 pandemic has caused distress across the globe. Many livelihoods and businesses are affected by the virus extensively. The hepatitis therapeutics market is negligibly impacted due to the outbreak as drugs and pharmacies come under the essential services and are exempt from the lockdown restrictions. However, supply chain and logistics disruptions during the strict lockdown had a minimal impact on the growth prospects.
The global hepatitis therapeutics market has been segmented as below:
|
Disease |
|
|
Drug Class |
|
|
Distribution Channel |
|
|
Region |
|
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Hepatitis Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Hepatitis Therapeutics Market Analysis and Forecasts, 2016–2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1.Pipeline Analysis
5.2.New Product Launch, Approvals & Patent Expiry
5.3.Regulatory Scenario
6. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Disease Type
6.1. Introduction & Definition
6.2. Market Value Forecast, by Disease Type, 2016–2026
6.2.1. Hepatitis A
6.2.2. Hepatitis B
6.2.3. Hepatitis C
6.2.4. Others
6.3. Market Attractiveness, by Disease Type
7. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Drug Class
7.1. Introduction & Definition
7.2. Market Value Forecast, by Drug Class, 2016–2026
7.2.1. Nucleotide Analog Reverse Transcriptase Inhibitor
7.2.2. NS5A Inhibitor
7.2.3. Multi Class Combination
7.2.4. Nucleotide Analog NS5B Polymerase Inhibitor
7.2.5. Interferon & Ribavirin
7.2.6. Others
7.3. Market Attractiveness, by Drug Class
8. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Distribution Channel
8.1. Introduction & Definition
8.2. Market Value Forecast, by Distribution Channel, 2016–2026
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
8.4. Market Attractiveness, by Distribution Channel
9. Global Hepatitis Therapeutics Market Analysis and Forecasts, by Region
9.1. Market Value Forecast, by Region
9.1.1. North America
9.1.2. Europe
9.1.3. Asia Pacific
9.1.4. Latin America
9.1.5. Middle East & Africa
9.2. Market Attractiveness, by Country/Region
10. North America Hepatitis Therapeutics Market Analysis and Forecast
10.1.Introduction
10.2.Market Value Forecast, by Disease Type, 2016–2026
10.2.1. Hepatitis A
10.2.2. Hepatitis B
10.2.3. Hepatitis C
10.2.4. Others
10.3.Market Value Forecast, by Drug Class, 2016–2026
10.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
10.3.2. NS5A Inhibitor
10.3.3. Multi Class Combination
10.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
10.3.5. Interferon & Ribavirin
10.3.6. Others
10.4.Market Value Forecast, by Distribution Channel, 2016–2026
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5.Market Value Forecast, by Country, 2016–2026
10.5.1. U.S.
10.5.2. Canada
10.6.Market Attractiveness, Analysis
10.6.1.By Disease Type
10.6.2. B Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Hepatitis Therapeutics Market Analysis and Forecast
11.1.Introduction
11.2.Market Value Forecast, by Disease, 2016–2026
11.2.1. Hepatitis A
11.2.2. Hepatitis B
11.2.3. Hepatitis C
11.2.4. Others
11.3.Market Value Forecast, by Drug Class, 2016–2026
11.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
11.3.2. NS5A Inhibitor
11.3.3. Multi-class Combination
11.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
11.3.5. Interferon & Ribavirin
11.3.6. Others
11.4.Market Value Forecast, by Distribution Channel, 2016–2026
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5.Market Value Forecast, by Country, 2016–2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6.Market Attractiveness, Analysis
11.6.1. By Disease Type
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country
12. Asia Pacific Hepatitis Therapeutics Market Analysis and Forecast
12.1.Introduction
12.2.Market Value Forecast, by Disease Type, 2016–2026
12.2.1. Hepatitis A
12.2.2. Hepatitis B
12.2.3. Hepatitis C
12.2.4. Others
12.3.Market Value Forecast, by Drug Class, 2016–2026
12.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
12.3.2. NS5A Inhibitor
12.3.3. Multi-class Combination
12.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
12.3.5. Interferon & Ribavirin
12.3.6. Others
12.4.Market Value Forecast, by Distribution Channel, 2016–2026
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5.Market Value Forecast, by Country, 2016–2026
12.5.1. Japan
12.5.2. China
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6.Market Attractiveness, Analysis
12.6.1. By Disease Type
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country
13. Latin America Hepatitis Therapeutics Market Analysis and Forecast
13.1.Introduction
13.2.Market Value Forecast, by Disease Type, 2016–2026
13.2.1. Hepatitis A
13.2.2. Hepatitis B
13.2.3. Hepatitis C
13.2.4. Others
13.3.Market Value Forecast, by Drug Class, 2016–2026
13.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
13.3.2. NS5A Inhibitor
13.3.3. Multi-class Combination
13.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
13.3.5. Interferon & Ribavirin
13.3.6. Others
13.4.Market Value Forecast, by Distribution Channel, 2016–2026
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5.Market Value Forecast, by Country, 2016–2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6.Market Attractiveness, Analysis
13.6.1. By Disease Type
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country
14. Middle East & Africa Hepatitis Therapeutics Market Analysis and Forecast
14.1.Introduction
14.2.Market Value Forecast, by Disease Type, 2016–2026
14.2.1. Hepatitis A
14.2.2. Hepatitis B
14.2.3. Hepatitis C
14.2.4. Others
14.3.Market Value Forecast, by Drug Class, 2016–2026
14.3.1. Nucleotide Analog Reverse Transcriptase Inhibitor
14.3.2. NS5A Inhibitor
14.3.3. Multi-class Combination
14.3.4. Nucleotide Analog NS5B Polymerase Inhibitor
14.3.5. Interferon & Ribavirin
14.3.6. Others
14.4.Market Value Forecast, by Distribution Channel, 2016–2026
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5.Market Value Forecast, by Country, 2016–2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.5. Rest of Middle East & Africa
14.6.Market Attractiveness, Analysis
14.6.1. By Disease Type
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country
15. Competition Landscape
15.1.Market Share Analysis, by Company (2017)
15.2. Company Profiles
15.2.1. Gilead Sciences, Inc.
15.2.2. F. Hoffmann-La Roche, Ltd.
15.2.3. Bristol Myers Squibb
15.2.4. Merck & Co., Inc.
15.2.5. AbbVie Inc.
15.2.6. NATCO Pharma Limited
15.2.7. Zydus Cadila
15.2.8. Hetero Healthcare Limited
15.2.9. LAURUS Labs
15.2.10. Cipla, Inc.
List of Figures
Figure 01: Global Hepatitis Therapeutics Market Value (US$ Mn) Forecast, 2016–2026
Figure 02: Global Hepatitis Therapeutics Market Value Share (%), by Disease Type (2017)
Figure 03: Global Hepatitis Therapeutics Market Value Share (%), by Drug Class (2017)
Figure 04: Global Hepatitis Therapeutics Market Value Share (%), by Distribution Channel (2017)
Figure 05: Global Hepatitis Therapeutics Market Value Share (%), by Region (2017)
Figure 06: Global Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 07: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis A, 2016–2026
Figure 08: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis B, 2016–2026
Figure 09: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hepatitis C, 2016–2026
Figure 10: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 11: Global Hepatitis Therapeutics Market Attractiveness,, by Disease Type, 2018–2026
Figure 12: Global Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 13: Global Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 14: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Nucleotide Analog Reverse Transcriptase Inhibitor, 2016–2026
Figure 15: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by NS5A Inhibitor, 2016–2026
Figure 16: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Multi-class Combination, 2016–2026
Figure 17: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Nucleotide Analog NS5B Polymerase Inhibitor, 2016–2026
Figure 18: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Interferon & Ribavirin, 2016–2026
Figure 19: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 20: Global Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 21: Global Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 22: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
Figure 23: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
Figure 24: Global Hepatitis Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
Figure 25: Global Hepatitis Therapeutics Market Value Share Analysis, by Region, 2018 and 2026
Figure 26: Global Hepatitis Therapeutics Market Attractiveness Analysis, by Region, 2018–2026
Figure 27: North America Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 28: North America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 29: North America Hepatitis Therapeutics Market AttractivenessAnalysis, by Country, 2018–2026
Figure 30: North America Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 31: North America Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 32: North America Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 33: North America Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 34: North America Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 35: North America Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 36: Europe Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 37: Europe Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 38: Europe Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 39: Europe Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 40: Europe Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 41: Europe Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 42: Europe Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 43: Europe Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 44: Europe Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 45: Asia Pacific Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 46: Asia Pacific Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 47: Asia Pacific Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 48: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 49: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 50: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 51: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 52: Asia Pacific Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 53: Asia Pacific Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 54: Latin America Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 55: Latin America Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 56: Latin America Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 57: Latin America Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 58: Latin America Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 59: Latin America Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 60: Latin America Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 61: Latin America Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 62: Latin America Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 63: Middle East & Africa Hepatitis Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 64: Middle East & Africa Hepatitis Therapeutics Market Value Share Analysis, by Country, 2018 and 2026
Figure 65: Middle East & Africa Hepatitis Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
Figure 66: Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Disease Type, 2018 and 2026
Figure 67: Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Disease Type, 2018–2026
Figure 68: Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Drug Class, 2018 and 2026
Figure 69: Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Drug Class, 2018–2026
Figure 70: Middle East & Africa Hepatitis Therapeutics Market Value Share (%), by Distribution Channel, 2018 and 2026
Figure 71: Middle East & Africa Hepatitis Therapeutics Market Attractiveness, by Distribution Channel, 2018–2026
Figure 72: Global Hepatitis Therapeutics Market Share, by Company, 2017
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes